RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter -: Associated Staphylococcus aureus infections

被引:70
作者
Cirioni, O
Giacometti, A
Ghiselli, R
Dell'Acqua, G
Orlando, F
Mocchegiani, F
Silvestri, C
Licci, A
Saba, V
Scalise, G
Balaban, N
机构
[1] Natl Inst Res & Therapy Elderly, Res Dept, Expt Anim Models Aging Unit, Ancona, Italy
[2] BalaPharm Int, Grafton, MA USA
[3] Tufts Univ, Cummings Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1086/498914
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Medical devices used in clinical practice are often associated with biofilm-associated staphylococcal infections. Methods. An in vitro antibiotic susceptibility assay of Staphylococcus aureus biofilms using 96-well polystyrene tissue-culture plates was performed to test the effects of RNAIII-inhibiting peptide ( RIP), ciprofloxacin, imipenem, and vancomycin. Efficacy studies were performed using a rat model of central venous catheter (CVC)-associated infection. Twenty-four hours after implantation, the catheters were filled with RIP (1 mg/mL). Thirty minutes later, rats were challenged, via the CVC, with cfu of S. aureus strain Smith diffuse. The antibiotic-lock 1.0 x 10(6) technique was begun 24 h later. Results. Minimum inhibitory concentrations of antibiotics in biofilms were at least 4-fold higher than those against the freely growing planktonic cells. When they were first treated with RIP, the cells in biofilms became as susceptible to antibiotics as did planktonic cells. These data were confirmed by the in vivo studies. In particular, when CVCs were treated with both RIP and antibiotics, the biofilm bacterial load was further reduced to 1 x 10(1) cfu/mL, and bacteremia was not detected, suggesting that there was 100% elimination of bacteremia and a 6 log(10) reduction in biofilm bacterial load. Conclusion. RIP significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of CVC-associated S. aureus infections.
引用
收藏
页码:180 / 186
页数:7
相关论文
共 46 条
[1]   Serial surveillance cultures of skin and catheter hub specimens from critically ill patients with central venous catheters: Molecular epidemiology of infection and implications for clinical management and research [J].
Atela, I ;
Coll, P ;
Rello, J ;
Quintana, E ;
Barrio, J ;
March, F ;
Sanchez, F ;
Barraquer, P ;
Ballus, J ;
Cotura, A ;
Prats, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (07) :1784-1790
[2]   Prevention of diseases caused by Staphylococcus aureus using the peptide RIP [J].
Balaban, N ;
Collins, LV ;
Cullor, JS ;
Hume, EB ;
Medina-Acosta, E ;
da Motta, OV ;
O'Callaghan, R ;
Rossitto, PV ;
Shirtliff, ME ;
da Silveira, LS ;
Tarkowski, A ;
Torres, JV .
PEPTIDES, 2000, 21 (09) :1301-1311
[3]   Prevention of Staphylococcal biofilm-associated infections by the quorum sensing inhibitor RIP [J].
Balaban, N ;
Stoodley, P ;
Fux, CA ;
Wilson, S ;
Costerton, JW ;
Dell'Acqua, G .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2005, (437) :48-54
[4]   A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci [J].
Balaban, N ;
Gov, Y ;
Giacometti, A ;
Cirioni, O ;
Ghiselli, R ;
Mocchegiani, F ;
Orlando, F ;
D'Amato, G ;
Saba, V ;
Scalise, G ;
Bernes, S ;
Mor, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2544-2550
[5]   Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis [J].
Balaban, N ;
Giacometti, A ;
Cirioni, O ;
Gov, Y ;
Ghiselli, R ;
Mocchegiani, F ;
Viticchi, C ;
Del Prete, MS ;
Saba, V ;
Scalise, G ;
Dell'Acqua, G .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (04) :625-630
[6]   Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells [J].
Balaban, N ;
Gov, Y ;
Bitler, A ;
Boelaert, JR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :340-345
[7]   Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus [J].
Balaban, N ;
Goldkorn, T ;
Nhan, RT ;
Dang, LB ;
Scott, S ;
Ridgley, RM ;
Rasooly, A ;
Wright, SC ;
Larrick, JW ;
Rasooly, R ;
Carlson, JR .
SCIENCE, 1998, 280 (5362) :438-440
[8]   Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating protein (TRAP) [J].
Balaban, N ;
Goldkorn, T ;
Gov, Y ;
Hirshberg, M ;
Koyfman, N ;
Matthews, HR ;
Nhan, RT ;
Singh, B ;
Uziel, O .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (04) :2658-2667
[9]   Global gene expression in Staphylococcus aureus biofilms [J].
Beenken, KE ;
Dunman, PM ;
McAleese, F ;
Macapagal, D ;
Murphy, E ;
Projan, SJ ;
Blevins, JS ;
Smeltzer, MS .
JOURNAL OF BACTERIOLOGY, 2004, 186 (14) :4665-4684
[10]   Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home [J].
Benoit, JL ;
Carandang, G ;
Sitrin, M ;
Arnow, P .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (04) :743-744